Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 15/20 | 0.42 |
| ▸ | GNRHR | P30968 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8963847 | 0.88 | DRD2 (0.53) | DRD2DRD4DRD3CTSSCYP3A4 | |
| SCHEMBL8963984 | 0.86 | DRD2 (0.51) | DRD2DRD4DRD3CTSSCYP3A4 | |
| SCHEMBL8963495 | 0.85 | DRD2 (0.50) | DRD2DRD4DRD3CTSSCYP3A4 | |
| Lifarizine SCHEMBL676318 | 0.83 | DRD2 (0.57) | DRD2DRD4DRD3CTSSCYP3A4 | |
| SCHEMBL8963977 | 0.82 | NPY5R (0.35) | DRD2DRD4DRD3GNRHRCYP3A4 | |
| Lifarizine SCHEMBL8963776 | 0.82 | DRD2 (0.56) | DRD2DRD4DRD3CTSSCYP3A4 | |
| SCHEMBL8964084 | 0.82 | DRD2 (0.52) | DRD2DRD4DRD3CTSSCYP3A4 | |
| SCHEMBL8963810 | 0.82 | LMNA (0.49) | DRD2DRD4DRD3CTSSGNRHR | |
| SCHEMBL8963673 | 0.80 | GNRHR (0.46) | DRD2DRD4DRD3CTSSGNRHR | |
| SCHEMBL9720664 | 0.80 | DRD2 (0.62) | DRD2DRD4DRD3CTSSGNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5514800-A | CALCIUM CHANNEL BLOCKERS, CEREBRAL ISCHEMIA | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1996-05-07 | — | — | US | disclosed |
| US-5276034-A | Cardiovascular disorders, nervous system disorders, diuretics, antiischemic agents or antispasmodic agents | SYNTEX PHARMACEUTICAL LTD. (GB) | 1994-01-04 | — | — | US | disclosed |
| US-5252736-A | Calcium channel antagonists | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1993-10-12 | — | — | US | disclosed |
| US-5142052-A | Cationic effect-driven carbinol/amine reaction | LABORATOIRES SYNTEX (FR) | 1992-08-25 | — | — | US | disclosed |
| EP-0289227-B1 | SUBSTITUTED IMIDAZOLYL-ALKYL-PIPERAZINE AND -DIAZEPINE DERIVATIVES | SYNTEX PHARMACEUTICALS LTD. (GB) | 1992-04-08 | — | — | EP | disclosed |
| US-5091428-A | Calcium channel blockers preferential for cerebral blood vessels | SYNTEX PHARMACEUTICALS, LTD. (BM) | 1992-02-25 | — | — | US | disclosed |
| US-5043447-A | Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1991-08-27 | — | — | US | disclosed |
| US-5010075-A | Antiepilepic, hypotensive, antiarrhythmia, antiischemic agent | SYNTEX PHARMACEUTICALS LTD. (GB) | 1991-04-23 | — | — | US | disclosed |
| US-4935417-A | CALCIUM CHANNEL BLOCKERS | SYNTEX PHARMACEUTICALS LTD. (BM) | 1990-06-19 | — | — | US | disclosed |
| US-4829065-A | Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1989-05-09 | — | — | US | disclosed |
| EP-0289227-A1 | Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives | SYNTEX PHARMACEUTICALS LTD. (GB) | 1988-11-02 | — | — | EP | disclosed |